About us
Introduction
Quality forum
Medicines UK structure
Medicines UK executive team
Our members
Associate members
Disclosure
Our core focus
Patients
Quality
Value
Sustainability
Partnership
Key issues
Introduction
Generic Pricing
Benefits to the NHS
Current supply issues
Patient access
Patient information
Freedom in market pricing
Getting to market
Sustainability
MHRA performance
Better Patent Regulation
Biosimilars
Falsified Medicines Directive
Industry-NHS guidance
About generics
Introduction
Industry overview
The generics industry
Studies on the generic medicines market in the UK
Generics FAQs
News
Current news
Information
Join us
Introduction
Associate Membership
Associate Members
Contact us
About us
Introduction
Quality forum
Medicines UK structure
Medicines UK executive team
Our members
Associate members
Disclosure
Our core focus
Patients
Quality
Value
Sustainability
Partnership
Key issues
Introduction
Generic Pricing
Benefits to the NHS
Current supply issues
Patient access
Patient information
Freedom in market pricing
Getting to market
Sustainability
MHRA performance
Better Patent Regulation
Biosimilars
Falsified Medicines Directive
Industry-NHS guidance
About generics
Introduction
Industry overview
The generics industry
Studies on the generic medicines market in the UK
Generics FAQs
News
Current news
Information
Join us
Introduction
Associate Membership
Associate Members
Contact us
Biosimilars
Current news
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2017
19.12.2017
Updated Statement on disruption to supply of generic medicines and concessionary pricing
14.12.2017
BREXIT Life Science Coalition Joint position paper media release
14.12.2017
UK Exiting from EU Life Science industry coalition position paper
08.12.2017
Statement on disruption to supply of generic medicines and concessionary pricing
01.12.2017
NHS England CCG guidance on routine prescribing
28.11.2017
Europe's life science industry urges Brexit breakthrough
27.11.2017
Reaction to the Government's Industrial Strategy White Paper
20.11.2017
Reaction to EMA decision
10.10.2017
Response to the publication the Care Quality Commission's annual State of Care report
22.09.2017
Medicines UK reaction to the Government's transition plan after Brexit
01.06.2017
Reaction to The European Medicines Agency (EMA) and the European Commission latest publications
03.05.2017
Bill Provides Department with Powers to Implement Pricing Agreement with Medicines UK
30.03.2017
Reaction to Next Steps on The NHS Five Year Forward View
Highlights
25.06.2020
Life Sciences Recovery Roadmap
16.06.2020
Reaction to dexamethasone treatment for Covid-19 patients
02.04.2020
Statement of intent for UK life sciences
25.03.2020
COVID-19 Medicines UK update
20.03.2020
Key worker welcome
18.03.2020
Covid-19 statement
04.03.2020
Response to today's CMA fines on anti-competitive agreements
06.02.2020
Reaction to the Government's document on the UK's approach to trade deals with non-EU nations